May 31, 2017

Digital Health Abstracts @ ASCO 2017

The remote patient management or tele-healthcare as a concept is only starting to take off in Oncology. The readouts, though limited by their small sample size, have shown positive impact of technology on care providers, patient outcomes and the overall cost burden. Normally, larger studies would be needed to validate […]
May 30, 2017

BMS @ASCO 2017

Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 More than 80 presentations (including16 oral presentations and 7 poster discussions), highlighting data from Company-sponsored studies, collaborations and IS research spanning 20 types of cancer, with focus on research of precision therapies […]
May 30, 2017

AstraZeneca @ASCO 2017

AstraZeneca (AZ), along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. With three new oncology […]
May 30, 2017

Amgen @ASCO 2017

Amgen announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, 2017. Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic […]
May 30, 2017

AbbVie @ASCO 2017

AbbVie will present a total of 23 abstracts across several tumor types including brain cancer, hematologic malignancies, breast cancer, lung cancer and other solid tumors. Researchers will present efficacy and safety data on depatuxizumab mafodotin, an antibody-drug conjugate (ADC) being studied for the treatment of adults with amplified EGFR newly […]
May 28, 2017

Liquid Biopsies in Cancer: Opportunities and Challenges

Liquid Biopsy is a term given to a minimally invasive method of analyzing Tumor cell DNA circulating in the blood. This is a useful and very promising approach and opens new vistas compared to the Biochemical Biomarkers and Tissue Biopsies dependent monitoring of cancer. However, it throws its own challenges […]